Albert Einstein College of Medicine's Novel Test Identifies Leukemia Patients Likely to Respond to New Therapy

Science Daily — Researchers at the Albert Einstein College of Medicine of Yeshiva University have discovered a genetic signature identifying cases of lymphoma that are uniquely susceptible to a newly developed molecular targeted therapy. As a result, physicians organizing clinical trials of the new therapy will be able to enroll patients who’ll be most likely to benefit from it.

>>> Discuss This Story

Back to news